南京醫藥(600713.SH):控股股東及其子公司向公司全資子公司中健信息增資
格隆匯3月14日丨南京醫藥(600713.SH)公佈,為滿足公司數字化轉型需求,提升公司核心競爭力,公司控股股東新工投資集團及其控股子公司紫金山科技擬以4.489053元/股的價格,共同對公司全資子公司中健信息進行增資。新工投資集團增資3,300.7745萬元,其中735.2941萬元計入註冊資本,剩餘部分2,565.4804萬元計入資本公積;紫金山科技增資3,168.7435萬元,其中705.8824萬元計入註冊資本,剩餘部分2,462.8611萬元計入資本公積;公司不參與本次增資。(以上增資價格及資本公積最終金額以經國資監管部門備案後的評估結果計算為準)
本次增資完成後,中健信息註冊資本由1,500萬元增至2,941.1765萬元,其中公司出資1,500萬元,佔其註冊資本的51%;新工投資集團出資735.2941萬元,佔其註冊資本的25%;紫金山科技出資705.8824萬元,佔其註冊資本的24%。中健信息同時更名為“南京新工數字科技有限責任公司”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.